#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #antibody drug conjugates

ADC Therapeutics Introduces Employee Inducement Grants

ADC Therapeutics SA (NYSE: ADCT), a prominent player in the field of antibody drug conjugates, recently announced a new initiative to support its growth strategy by offering inducement grants to its newly onboarded employees. On September 2, 2025, the company granted options to purchase a total of 29,700 common shares to two new employees as part of this program, aimed at enhancing employee motivation and performance.

Purpose of the Grants

The primary goal of these grants is to serve as a material inducement for employees joining ADC Therapeutics. According to the company, this move is designed to align with its Inducement Plan, which is specifically tailored to reward individuals who are expected to significantly contribute to the organization's success. In doing so, ADC Therapeutics hopes to attract top talent and ensure they are motivated to perform at their best.

The decision to introduce this grant program falls under the jurisdiction of the Compensation Committee, which oversees employee remuneration and incentives. This committee approved the grants based on the company's adherence to the employment inducement exemption outlined in the NYSE's Listed Company Manual Rule 303A.08.

Vesting Schedule

As part of the grant's terms, shares will begin to vest 25% on the first anniversary of the grant date. Following this initial vesting period, the remaining shares will vest at a rate of 1/48th each month thereafter, leading to full vesting after the fourth anniversary of the grant, provided the employees remain with ADC Therapeutics.

ADC Therapeutics Overview

Headquartered in Lausanne, Switzerland, with additional operations in London and New Jersey, ADC Therapeutics has earned a reputation as a leader in the development of innovative therapies using antibody drug conjugates. The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after failing two or more lines of systemic therapy.

In addition to ZYNLONTA, ADC Therapeutics is actively advancing a next-generation PSMA-targeting ADC designed with a unique exatecan-based payload and hydrophilic linker. This strategic focus on innovation underscores the company's commitment to improving treatment outcomes for patients facing serious medical challenges.

Looking Ahead

The introduction of the inducement grants signifies ADC Therapeutics’ commitment to fostering a robust workforce capable of driving its growth and continued innovation in the biopharmaceutical sector. By attracting top-tier talent and providing them with incentives tied to their performance, ADC Therapeutics aims to solidify its standing as a pioneer in the antibody drug conjugate market.

As the company navigates an increasingly competitive landscape, the motivation of its employees through strategic compensation initiatives like this will be crucial in achieving its long-term objectives. Stakeholders and market observers will be keenly watching how these changes impact overall company performance and employee satisfaction in the coming years.

For further updates, please visit ADC Therapeutics' official website or follow them on LinkedIn for the latest news on their groundbreaking therapies and workplace initiatives.